Efficacy of osimertinib resumption with dabrafenib and trametinib for elderly patients with EGFR -mutated lung adenocarcinoma harboring acquired BRAF V600E resistant mutation resistant to osimertinib
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf059 ↗Kurz gefasst
Fallbericht in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Yusuke Hirata und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe-shi, Saitama 350-8550, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma of Lung. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Department of Respiratory Medicine.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) provides survival benefits in non-small cell lung cancer (NSCLC) with EGFR mutations. The acquired v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation is present in ⁓3% of cases as a resistance mechanism to osimertinib, a third-generation EGFR TKI. However, there is no consensus on the optimal therapy for patients with osimertinib-resistant EGFR-mutated NSCLC harboring a BRAF V600E mutation. Here, we present the case of the oldest patient treated with a combination of osimertinib, dabrafenib, and trametinib. In an 81-year-old woman, osimertinib resumption with reduced doses of dabrafenib and trametinib showed therapeutic efficacy with an acceptable safety profile after osimertinib failure. The present case suggests that under active dose modifications of dabrafenib and trametinib, triple TKI therapy exerts therapeutic effects in elderly patients with osimertinib-resistant EGFR-mutated NSCLC and a BRAF V600E mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe-shi, Saitama 350-8550, Japan.
- Department of General Thoracic Surgery, Saitama Medical Center, Saitama Medical University, 1981 Kamoda, Kawagoe-shi, Saitama, 350-8550, Japan.
Förderung
- Department of Respiratory Medicine
Zitieren
APA
Hirata, Y., Koyama, N., Kuramoto, J., Nishimura, H., Yokosuka, S., Shiraishi, K., Matsumoto, I., Takahashi, T., Kuwabara, Y., Ogawa-Kobayashi, Y., Kikuchi, S., Sakai, K., Kyoyama, H., Moriyama, G., Gika, M., & Uematsu, K. (2025). Efficacy of osimertinib resumption with dabrafenib and trametinib for elderly patients with EGFR -mutated lung adenocarcinoma harboring acquired BRAF V600E resistant mutation resistant to osimertinib. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf059
Vancouver
Hirata Y, Koyama N, Kuramoto J, Nishimura H, Yokosuka S, Shiraishi K, et al. Efficacy of osimertinib resumption with dabrafenib and trametinib for elderly patients with EGFR -mutated lung adenocarcinoma harboring acquired BRAF V600E resistant mutation resistant to osimertinib. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf059
BibTeX
@article{Hirata2025,
author = {Hirata, Yusuke and Koyama, Nobuyuki and Kuramoto, Joji and Nishimura, Hiroaki and Yokosuka, Shin and Shiraishi, Kouta and Matsumoto, Itsuka and Takahashi, Tomoyuki and Kuwabara, Yoshiki and Ogawa-Kobayashi, Yumiko and Kikuchi, Satoshi and Sakai, Kosuke and Kyoyama, Hiroyuki and Moriyama, Gaku and Gika, Masatoshi and Uematsu, Kazutsugu},
title = {Efficacy of osimertinib resumption with dabrafenib and trametinib for elderly patients with EGFR -mutated lung adenocarcinoma harboring acquired BRAF V600E resistant mutation resistant to osimertinib},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf059}
}
EUVIMED